Articles from Actinogen Medical

Final, 247th participant randomized and commences treatment in Actinogen’s XanaMIA pivotal phase 2b/3 Alzheimer’s trial

On track for interim analysis in late January 2026 and topline final results November 2026

By Actinogen Medical · Via GlobeNewswire · December 18, 2025

Actinogen achieves agreement with the FDA in a Type C meeting on the manufacturing, clinical and nonclinical activities required for a future US marketing approval of Xanamem for Alzheimer’s disease

Current XanaMIA pivotal phase 2/3 trial on track for interim analysis in January 2026 and final results late 2026 with trial enrolment expected to close in Q4 2025

By Actinogen Medical · Via GlobeNewswire · September 15, 2025

Actinogen provides pivotal Alzheimer’s trial enrolment update and other business news

Phase 2b/3 Alzheimer’s trial enrolment expected to reach 100 this quarter, triggering an interim analysis 6 months later

By Actinogen Medical · Via GlobeNewswire · April 30, 2025